Details for Patent: 12,552,749

« Back to Dashboard

Which drugs does patent 12,552,749 protect, and when does it expire?

Patent 12,552,749 protects OMCAZIO and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 12,552,749

Title:	Cabozantinib compositions and methods of use
Abstract:	The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.
Inventor(s):	Fang-Yu Liu, K.C. Sung, Yu Zhang, Shang Wei Qin, John Duan, George Kraft
Assignee:	Handa Oncology LLC
Application Number:	US19/184,689
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 12,552,749

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,552,749					TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,552,749					TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,552,749					TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,749					TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,749					TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,749					TREATMENT OF ADVANCED RENAL CELL CARCINOMA

International Family Members for US Patent 12,552,749

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2024215796
China	120417903
European Patent Office	4658271
Japan	2026505189
South Korea	20250136810
Taiwan	202444365